• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哥伦比亚人群中诊断为黑色素瘤患者的 BRAF、NRAS 和 C-KIT 基因突变。

Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.

机构信息

Hospital Universitario-Centro Dermatológico Federico Lleras Acosta-CDFLLA, Bogota 111511, Colombia.

出版信息

Biomed Res Int. 2020 Jul 22;2020:2046947. doi: 10.1155/2020/2046947. eCollection 2020.

DOI:10.1155/2020/2046947
PMID:32775409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7396105/
Abstract

INTRODUCTION

Mutations in the BRAF, NRAS, and C-KIT genes have been associated with the histopathological characteristics of melanoma. Likewise, the incidence of each of these subtypes changes according to the geographical origin of the population analyzed.

OBJECTIVE

To determine the mutation frequency in exons 11 and 15 of the BRAF gene, exons 1 and 2 of the NRAS gene, and exons 11, 13, and 17 of the C-KIT gene and to relate it with histological subtypes in patients from a region with high levels of ultraviolet radiation. . The clinicopathological characteristics of 54 cutaneous melanoma samples were analyzed. Mutation analysis was performed via qPCR on paraffin-embedded tumor tissue samples using probes specific for the V600E mutation. Amplification of exons 11 and 15 of the BRAF gene, exons 1 and 2 of the NRAS gene, and exons 11, 13, and 17 of the C-KIT gene was performed for subsequent sequencing using the Sanger method.

RESULT

The most frequent histological subtype in the analyzed sample was lentigo maligna/lentigo maligna melanoma (52%) followed by acral lentiginous melanoma (20%). The BRAF-V600 variant was the most frequent (63.6%). The most frequent (54%) mutation in NRAS was p.Lys5∗. In the C-KIT gene, only the Val560Ala mutation was found.

CONCLUSION

Differences in histological subtypes and mutations in the BRAF, NRAS, and C-KIT genes were found in the analyzed population. This indicates that environmental and genetic factors significantly influence the introduction of the disease in this geographic region.

摘要

简介

BRAF、NRAS 和 C-KIT 基因的突变与黑色素瘤的组织病理学特征有关。同样,这些亚型的发病率根据分析人群的地理来源而变化。

目的

确定 BRAF 基因外显子 11 和 15、NRAS 基因外显子 1 和 2 以及 C-KIT 基因外显子 11、13 和 17 中的突变频率,并将其与来自高紫外线辐射地区的患者的组织学亚型相关联。分析了 54 例皮肤黑色素瘤样本的临床病理特征。通过针对 V600E 突变的探针,在石蜡包埋的肿瘤组织样本上使用 qPCR 进行突变分析。对 BRAF 基因外显子 11 和 15、NRAS 基因外显子 1 和 2 以及 C-KIT 基因外显子 11、13 和 17 进行扩增,然后使用 Sanger 法进行测序。

结果

在分析的样本中,最常见的组织学亚型是良性黑色素瘤/恶性黑色素瘤(52%),其次是肢端黑色素瘤(20%)。BRAF-V600 变体是最常见的(63.6%)。NRAS 中最常见的(54%)突变是 p.Lys5∗。在 C-KIT 基因中,仅发现 Val560Ala 突变。

结论

在分析的人群中发现了 BRAF、NRAS 和 C-KIT 基因的组织学亚型和突变的差异。这表明环境和遗传因素对该地理区域疾病的发生有重大影响。

相似文献

1
Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.哥伦比亚人群中诊断为黑色素瘤患者的 BRAF、NRAS 和 C-KIT 基因突变。
Biomed Res Int. 2020 Jul 22;2020:2046947. doi: 10.1155/2020/2046947. eCollection 2020.
2
Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.斯洛文尼亚晚期黑色素瘤患者中 BRAF、NRAS 和 c-KIT 突变的流行情况。
Radiol Oncol. 2018 Apr 26;52(3):289-295. doi: 10.2478/raon-2018-0017.
3
Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.口腔黏膜黑色素瘤中BRAF、NRAS、KIT和GNAQ/GNA11的突变扫描:57例研究
J Oral Pathol Med. 2016 Apr;45(4):295-301. doi: 10.1111/jop.12358. Epub 2015 Sep 24.
4
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.肢端雀斑样黑素瘤瑞典患者样本中的 KIT、NRAS、BRAF 和 PTEN 突变。
J Dermatol Sci. 2013 Dec;72(3):284-9. doi: 10.1016/j.jdermsci.2013.07.013. Epub 2013 Aug 8.
5
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.日本黑色素瘤患者中与BRAF、NRAS和KIT突变相关的临床特征。
J Dermatol Sci. 2015 Oct;80(1):33-7. doi: 10.1016/j.jdermsci.2015.07.012. Epub 2015 Jul 26.
6
Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.原发性皮肤黑色素瘤的临床病理特征及突变分析
Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.
7
Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.致癌 BRAF、NRAS、c-KIT 和 MITF 在皮肤和黏膜黑色素瘤中的预后和预测价值。
J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1530-8. doi: 10.1111/jdv.12910. Epub 2015 Jan 26.
8
BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.肢端黑色素瘤中 BRAF、KIT 和 NRAS 基因突变。
Am J Clin Pathol. 2020 Apr 15;153(5):664-671. doi: 10.1093/ajcp/aqz209.
9
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.在一系列发生于鼻窦的原发性黑色素瘤中存在癌基因异常:NRAS 突变和 cyclin D1 扩增比 KIT 或 BRAF 突变更为常见。
Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025. Epub 2013 May 9.
10
[ Spectrum of oncogene mutations is different in melanoma subtypes].[黑色素瘤亚型中癌基因突变谱不同]
Mol Biol (Mosk). 2015 Nov-Dec;49(6):1022-9. doi: 10.7868/S0026898415060166.

引用本文的文献

1
Polygenic Risk Score Analysis of 37 SNPs Associated with Melanoma Risk in Colombian Population.哥伦比亚人群中与黑色素瘤风险相关的37个单核苷酸多态性的多基因风险评分分析。
Int J Mol Sci. 2025 May 14;26(10):4674. doi: 10.3390/ijms26104674.
2
RIPK4 Downregulation Reduces ABCG2 Expression, Increasing BRAF-Mutated Melanoma Cell Susceptibility to Cisplatin- and Doxorubicin-Induced Apoptosis.RIPK4表达下调可降低ABCG2的表达,增加BRAF突变的黑色素瘤细胞对顺铂和阿霉素诱导凋亡的敏感性。
Biomolecules. 2024 Dec 10;14(12):1573. doi: 10.3390/biom14121573.
3
Molecular Susceptibility and Treatment Challenges in Melanoma.

本文引用的文献

1
Class Matters: Sensitivity of -Mutant Melanoma to MAPK Inhibition.阶级问题:-突变黑色素瘤对 MAPK 抑制的敏感性。
Clin Cancer Res. 2018 Dec 15;24(24):6107-6109. doi: 10.1158/1078-0432.CCR-18-1795. Epub 2018 Jul 24.
2
Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.基因组和转录组分析揭示黑色素瘤演进过程中关键信号通路的逐渐破坏。
Cancer Cell. 2018 Jul 9;34(1):45-55.e4. doi: 10.1016/j.ccell.2018.06.005.
3
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.
黑色素瘤的分子易感性和治疗挑战。
Cells. 2024 Aug 20;13(16):1383. doi: 10.3390/cells13161383.
4
Comparative Analysis of the Effect of the BRAF Inhibitor Dabrafenib in 2D and 3D Cell Culture Models of Human Metastatic Melanoma Cells.BRAF 抑制剂达拉非尼在人转移性黑色素瘤细胞 2D 和 3D 细胞培养模型中的疗效比较分析。
In Vivo. 2024 Jul-Aug;38(4):1579-1593. doi: 10.21873/invivo.13608.
5
BRAF-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.BRAF 突变型黑色素瘤在拉丁美洲的诊疗历程:专家建议从诊断到治疗。
Cancer Control. 2024 Jan-Dec;31:10732748241251572. doi: 10.1177/10732748241251572.
6
Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.POLARIS-01 二期临床试验 5 年随访结果:特瑞普利单抗作为中国晚期黑色素瘤患者的单药挽救治疗。
Oncologist. 2024 Jun 3;29(6):e822-e827. doi: 10.1093/oncolo/oyae045.
7
Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.评估 RAS-RAF-MAPK 通路突变状态在健康皮肤、良性痣和皮肤黑素瘤中的作用:使用液滴数字 PCR 的初步研究。
Int J Mol Sci. 2024 Feb 15;25(4):2308. doi: 10.3390/ijms25042308.
8
The role of angiogenesis in melanoma: Clinical treatments and future expectations.血管生成在黑色素瘤中的作用:临床治疗与未来展望。
Front Pharmacol. 2022 Dec 15;13:1028647. doi: 10.3389/fphar.2022.1028647. eCollection 2022.
9
3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.3'UTR-CDKN2A 和 CDK4 种系变异与皮肤黑色素瘤易感性相关。
In Vivo. 2021 May-Jun;35(3):1529-1536. doi: 10.21873/invivo.12406.
《国家癌症报告:第一部分:全国癌症统计数据》
Cancer. 2018 Jul 1;124(13):2785-2800. doi: 10.1002/cncr.31551. Epub 2018 May 22.
4
Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.提高黑素细胞痣分类的准确性:BRAF V600E 表达与独特的组织形态学特征相关。
J Am Acad Dermatol. 2018 Aug;79(2):221-229. doi: 10.1016/j.jaad.2018.03.052. Epub 2018 Apr 11.
5
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.癌症中 BRAF 改变的分类:可操作突变的新合理治疗策略。
Oncogene. 2018 Jun;37(24):3183-3199. doi: 10.1038/s41388-018-0171-x. Epub 2018 Mar 15.
6
Factors Related to Nevus-Associated Cutaneous Melanoma: A Case-Case Study.与痣相关的皮肤黑色素瘤的相关因素:病例对照研究。
J Invest Dermatol. 2018 Aug;138(8):1816-1824. doi: 10.1016/j.jid.2017.12.036. Epub 2018 Mar 7.
7
Cutaneous melanoma primary site is linked to nevus density.皮肤黑色素瘤的原发部位与痣密度有关。
Oncotarget. 2017 Oct 24;8(58):98876-98886. doi: 10.18632/oncotarget.22016. eCollection 2017 Nov 17.
8
Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.影响BRAF突变概率的变量:一项关于黑色素瘤中BRAFV600突变状态的二代测序、非干预性研究。
PLoS One. 2017 Nov 27;12(11):e0188602. doi: 10.1371/journal.pone.0188602. eCollection 2017.
9
Nodular melanoma is less likely than superficial spreading melanoma to be histologically associated with a naevus.结节性黑色素瘤在组织学上与痣相关的可能性低于浅表扩散性黑色素瘤。
Med J Aust. 2017 Oct 16;207(8):333-338. doi: 10.5694/mja17.00232.
10
Acral melanoma foot lesions. Part 1: epidemiology, aetiology, and molecular pathology.肢端黑色素瘤足部病变。第一部分:流行病学、病因学和分子病理学。
Clin Exp Dermatol. 2017 Dec;42(8):845-848. doi: 10.1111/ced.13243. Epub 2017 Sep 22.